

# Global Pharmaceutical Continuous Manufacturing Market 2023-2029

<https://marketpublishers.com/r/GFE079B9C034EN.html>

Date: February 2023

Pages: 90

Price: US\$ 2,950.00 (Single User License)

ID: GFE079B9C034EN

## Abstracts

For decades, pharmaceutical firms have manufactured their products in batches. To streamline production, manufacturers have begun to apply continuous manufacturing technologies to the pharmaceutical production process. Continuous manufacturing is a method for manufacturing pharmaceutical products from end-to-end on a single, uninterrupted production line. This continuous production eliminates built-in production gaps and can shorten manufacturing times from months to days. Where batch manufacturing requires transporting, testing, and re-feeding materials from one process to the next, continuous processes execute all testing, feeding, and processing inline. The global pharmaceutical continuous manufacturing market was estimated at USD 1,778 million in 2022 and is expected to hit USD 5,241 million by 2029, registering a CAGR of 16.7% from 2023 to 2029 as per the latest market estimates.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical continuous manufacturing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, drug type, source, and region. The global market for pharmaceutical continuous manufacturing can be segmented by product: active pharmaceutical ingredients (APIs), finished dosage form (FDF). According to the research, the APIs segment had the largest share in the global pharmaceutical continuous manufacturing market. Pharmaceutical continuous manufacturing market is further segmented by drug type: large molecules, small molecules. In 2022, the small

molecules segment made up the largest share of revenue generated by the pharmaceutical continuous manufacturing market. Based on source, the pharmaceutical continuous manufacturing market is segmented into: in-house, outsourced. Among these, the in-house segment was accounted for the highest revenue generator in 2022. On the basis of region, the pharmaceutical continuous manufacturing market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).

## Market Segmentation

By product: active pharmaceutical ingredients (APIs), finished dosage form (FDF)

By drug type: large molecules, small molecules

By source: in-house, outsourced

By region: Asia Pacific, Europe, North America, Rest of the World (RoW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including Abbott Laboratories, Ajinomoto Althea, Inc., Almac Group, Applikon Biotechnology B.V. (Getinge AB), Cipla Limited, Continuous Pharmaceuticals, Inc., Corden Pharma GmbH (International Chemical Investors S.E.), Eli Lilly and Company, Eppendorf SE, FUJIFILM Holdings Corporation, GEA Group AG, Glatt GmbH, GSK plc, Hovione Limited, Johnson & Johnson, L.B. Bohle Maschinen und Verfahren GmbH, Lonza Group AG, Merck KGaA, Novartis AG, Pall Corporation, Pfizer Inc., Recipharm AB, SEQENS SAS, Shanghai Pharmaceuticals Holding Co., Ltd., Shionogi & Company, Limited, SK biotek Ireland Limited, Syntegon Technology GmbH, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, WuXi Biologics Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

**\*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES**

## Scope of the Report

To analyze and forecast the market size of the global pharmaceutical continuous manufacturing market.

To classify and forecast the global pharmaceutical continuous manufacturing market based on product, drug type, source, region.

To identify drivers and challenges for the global pharmaceutical continuous manufacturing market.

To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pharmaceutical continuous manufacturing market.

To identify and analyze the profile of leading players operating in the global pharmaceutical continuous manufacturing market.

### Why Choose This Report

Gain a reliable outlook of the global pharmaceutical continuous manufacturing market forecasts from 2023 to 2029 across scenarios.

Identify growth segments for investment.

Stay ahead of competitors through company profiles and market data.

The market estimate for ease of analysis across scenarios in Excel format.

Strategy consulting and research support for three months.

Print authentication provided for the single-user license.

## Contents

### **PART 1. INTRODUCTION**

Report description  
Objectives of the study  
Market segment  
Years considered for the report  
Currency  
Key target audience

### **PART 2. METHODOLOGY**

### **PART 3. EXECUTIVE SUMMARY**

### **PART 4. MARKET OVERVIEW**

Introduction  
Drivers  
Restraints

### **PART 5. MARKET BREAKDOWN BY PRODUCT**

Active pharmaceutical ingredients (APIs)  
Finished dosage form (FDF)

### **PART 6. MARKET BREAKDOWN BY DRUG TYPE**

Large molecules  
Small molecules

### **PART 7. MARKET BREAKDOWN BY SOURCE**

In-house  
Outsourced

### **PART 8. MARKET BREAKDOWN BY REGION**

Asia Pacific

Europe

North America

Rest of the World (RoW)

## **PART 9. KEY COMPANIES**

Abbott Laboratories

Ajinomoto Althea, Inc.

Almac Group

Applikon Biotechnology B.V. (Getinge AB)

Cipla Limited

Continuus Pharmaceuticals, Inc.

Corden Pharma GmbH (International Chemical Investors S.E.)

Eli Lilly and Company

Eppendorf SE

FUJIFILM Holdings Corporation

GEA Group AG

Glatt GmbH

GSK plc

Hovione Limited

Johnson & Johnson

L.B. Bohle Maschinen und Verfahren GmbH

Lonza Group AG

Merck KGaA

Novartis AG

Pall Corporation

Pfizer Inc.

Recipharm AB

SEQENS SAS

Shanghai Pharmaceuticals Holding Co., Ltd.

Shionogi & Company, Limited

SK biotek Ireland Limited

Syntegon Technology GmbH

Thermo Fisher Scientific Inc.

Vertex Pharmaceuticals Incorporated

WuXi Biologics Co., Ltd.

**\*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES**

**DISCLAIMER**

## I would like to order

Product name: Global Pharmaceutical Continuous Manufacturing Market 2023-2029

Product link: <https://marketpublishers.com/r/GFE079B9C034EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFE079B9C034EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970